Noscendo gets financing for diagnosing blood infections

十月 31, 2018

Noscendo closes financing round for platform that detects pathogens in blood infections

Estimated reading time: 2 minutes

Share on social media

  • 鏈接已復制


The diagnostic procedures developed by Noscendo help intensive care clinicians identify the pathogens in bloodstream-associated infections. Munich-based family office Wieland Capital, HTGF and three business angels with in-depth knowledge of the diagnostics industry are jointly investing a seven-digit sum of Euros into Noscendo GmbH. These funds will enable Noscendo to receive approval for its medical device and prepare for the market entry of Noscendo’s proprietary diagnostic platform.


In two-thirds of all cases, existing diagnostic procedures do not allow intensive care clinicians to draw conclusions on the pathogens causing bloodstream-associated infections such as sepsis (“blood poisoning”) and endocarditis (inflammation of the inner layers of the heart). Therapy options are therefore very often limited to administering broad-band antibiotics. Unspecific therapy leads to high mortality rates and severe complications in many patients, and also accentuates the issue of resistant hospital pathogens.

Three men — including two co-founders of Noscendo, Dr.  Philip Stevens and Dr. Peter Haug — look at a computer screen together.

Noscendo identifies bacteria, fungi, viruses and parasites in the patient’s bloodstream via Next Generation Sequencing (NGS) and is able to assess the relevance of each pathogen using proprietary algorithms. In poly-microbial infections, the diagnostic platform differentiates the primary pathogens across various classes. Using Noscendo’s analytical results, intensive care clinicians can treat patients much more specifically by administering the most effective therapeutic drug according to the identified relevant pathogen.


“We are absolutely delighted to have won over a powerful consortium of investors in the form of Wieland Capital as lead investor, HTGF and three highly experienced business angels, who will be a great support in further developing our approach,” says Dr. Philip Stevens, CEO of Noscendo. Robert Wieland, Managing Director of the Munich-based family office Wieland Capital, strongly believes in the tech­no­logy: “Noscendo’s diagnostic platform for analysis and identification of pathogens provides far more precise and reliable results and has the potential to define a new gold standard in intensive care.”

Financial resources from the investment round will be utilized for CE certification of Noscendo’s diagnostic platform as a medical device (“Software as a Medical Device”) and preparation for market entry. “Together with innovative intensive care clinicians and sophisticated partners, we will introduce our diagnostic services as a mail-in business as well as on-site in selected hospital laboratories,” says Dr. Peter Haug, CEO and Head of Business Development.


“The excellent feedback from clinical directors and the huge experience of the team and the business angels provide ideal conditions for Noscendo to set a new standard in the pathogen detection of life-threatening blood stream infections,” says Dr. Fabian Mohr.

Related insights

  • Best practices on how to accelerate innovation together


    Best practices on how to accelerate innovation together

    Learn more
  • Start-ups: four ways to avoid failing at the first hurdle


    Start-ups: four ways to avoid failing at the first hurdle

    Learn more
  • The value of corporates working with start-ups


    The value of corporates working with start-ups

    Learn more

Interested in becoming a start-up partner with Philips Ventures?

Changing healthcare

Together, we’re changing healthcare

Philips Ventures champions innovative start-ups with breakthrough solutions.

You are about to visit a Philips global content page


You are about to visit a Philips global content page


使用最新版 Microsoft Edge、Google Chrome 或 Firefox 瀏覽本網站效果最佳。